Drug Approval | April 02, 2024
AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer
Application based on results from the TROPION-Breast01 Phase III trial
Application based on results from the TROPION-Breast01 Phase III trial
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
Combination shows consistent benefit across prespecified post-progression outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
The validations confirm the completion of the applications and commence the scientific review process
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Subscribe To Our Newsletter & Stay Updated
